Start here if you're new
what it is
Anebulo develops treatments for cannabis poisoning and acute cannabinoid intoxication.
how it gets paid
Last year Anebulo Pharma made n/a in revenue. Selonabant oral program was the main engine at $0M, or 40% of sales.
what just happened
Anebulo posted -$0.10 EPS and still showed no revenue.
At a glance
C++ balance sheet — some cracks in the foundation
-$0.25 fy2025 eps est
$0M fy2023 rev est
1.2 beta
~$22M market cap
xvary composite: 30/100 — weak
What they do
Anebulo develops treatments for cannabis poisoning and acute cannabinoid intoxication.
It has 2 employees and 1 lead molecule, selonabant. That is not scale. It is focus. If your hospital drug works, leaving the story gets harder because the whole company is built around 1 rescue medicine and 2 use cases.
How they make money
n/a
annual revenue
Selonabant oral program
$0M
Selonabant IV program
$0M
Acute cannabis toxicity pipeline
$0M
Corporate and other
$0M
The products that matter
phase 1 intravenous drug candidate
selonabant (ANEB-001)
lead asset · $22M company
first patients were dosed in a Phase 1 single ascending dose study in September 2025. Data is expected in 2026, which means the science still has to do almost all of the heavy lifting.
binary catalyst
public market access
listing status
Nasdaq exit effective feb 27, 2026
this is not a commercial product, but it matters anyway. Once a tiny biotech leaves Nasdaq at $0.48, liquidity becomes part of your risk model whether you wanted it there or not.
structural risk
capital markets credibility
abandoned restructuring plan
21% drop · dec 22, 2025
the company announced then abandoned a reverse stock split and limited tender offer on December 22, 2025. For a micro-cap name already under pressure, that kind of reversal damages trust as much as price.
trust watch
Key numbers
-$0.25
fy2025 eps est
$0M
fy2023 rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ANEB right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Anebulo posted -$0.10 EPS and still showed no revenue.
The latest quarter showed EPS of -$0.10, down 100% vs. prior year. Revenue was not reported, which leaves the business story stuck on cash burn.
$0M
revenue
-$0.10
eps
?
gross margin
the number that mattered
EPS was -$0.10, which means the company is still losing money on every quarter it reports.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
Anebulo's risk stack is unusually concentrated: one Phase 1 asset, one tiny equity base, and one exchange exit that already happened. You do not need a long list here. You need the few risks that can actually break the story.
high
No revenue base
TTM revenue is $0M. That means the company is still funding experiments, not a sales machine.
could put the full $22M market cap under pressure
high
Delisting overhang
In February 2026, the company said it intends to delist from Nasdaq and deregister with the SEC. That can hit liquidity fast.
can reduce tradable value by 100% for some holders
med
One-drug dependence
The company has 1 lead candidate, selonabant, and 2 employees. If that program slips, there is no backup business.
puts 100% of product value on 1 molecule
This is a binary setup. If selonabant works, you have a story. If it stalls, you have a shell.
source: institutional data · regulatory filings · risk analysis
Pay attention to
listing
Delisting is now a current condition, not a warning label
The voluntary delisting from Nasdaq Capital Market became effective on February 27, 2026. From here, trading friction is part of the stock.
clinical
Phase 1 data is the one clean upside catalyst on the page
First patients were dosed in September 2025, and data is expected in 2026. If anything changes the narrative, it is this.
balance sheet
A $22M market cap leaves very little room for financing mistakes
Small-cap biotech dilution can reset the equity story fast. The C++ balance sheet grade grade is the warning sign here.
trust
The December 2025 reversal still matters
Announcing then abandoning a reverse split and tender plan, followed by a 21% drop, is the kind of sequence investors remember.
Analyst rankings
coverage depth
thin
small-cap, delisted biotech names rarely get rich analyst coverage. you are closer to first principles than consensus here.
source: institutional data
Institutional activity
institutional ownership data for ANEB is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$0
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive